Gate Bioscience

Gate Bioscience is developing a first-in-class platform for protein elimination using small molecules that gate the secretory translocon, preventing specific disease-causing proteins from being secreted. This approach targets over 1,000 extracellular proteins linked to disease, offering potential advantages in tissue penetration and oral administration over biologics. The company is private, pre-clinical, and leverages its proprietary Molecular Gate Discovery Platform™ to systematically discover drugs for a wide range of conditions.

Molecular Gate Discovery Platform™: A proprietary engine combining a privileged small molecule library, specialized secretion-focused assays, and deep secretory pathway biology expertise to discover drugs that gate the secretory translocon and block specific extracellular proteins from being secreted.

Gate competes with established biologic therapies (antibodies) that neutralize extracellular proteins and emerging intracellular protein degradation technologies (e.g., PROTACs, LYTACs). Its unique proposed value is oral small molecule intervention at the point of secretion, a mechanism distinct from both extracellular neutralization and intracellular post-translational degradation.